Agilent Technologies (Santa Clara, California) plans to separate into two publicly traded companies: one in life sciences, diagnostics, and applied markets that will retain the Agilent name, and another that will encompass Agilent?s current portfolio of electronic measurement products.
Agilent Technologies (Santa Clara, California) plans to separate into two publicly traded companies: one in life sciences, diagnostics, and applied markets that will retain the Agilent name, and another that will encompass Agilent’s current portfolio of electronic measurement products.
The new electronic measurement company will be an electronic measurement company in major markets including communications, aerospace and defense, and industrial, computers, and semiconductors.
Agilent says it believes that the separation will result in material benefits to the standalone companies, including greater management focus on the distinct businesses of life sciences, diagnostics, and applied markets, and electronic measurement; ability for the life sciences, diagnostics, and applied markets company to devote resources to the higher-growth life sciences, diagnostics, and applied markets business, while reducing exposure to the more cyclical electronic measurement industry; ability for the electronic measurement company to devote resources to its own growth that were previously used to capitalize life sciences, diagnostics, and applied markets; and two independent and unique investment profiles. Additionally, both companies will be well capitalized, having strong balance sheets and investment-grade profiles with target debt-to-EBITDA ratios below 2.0x.
An LC–HRMS Method for Separation and Identification of Hemoglobin Variant Subunits
March 6th 2025Researchers from Stanford University’s School of Medicine and Stanford Health Care report the development of a liquid chromatography high-resolution mass spectrometry (LC–HRMS) method for identifying hemoglobin (Hb) variants. The method can effectively separate several pairs of normal and variant Hb subunits with mass shifts of less than 1 Da and accurately identify them in intact-protein and top-down analyses.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.